November 1, 2024
admin
Sai Life Sciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate @ Chanakyanipothi.com
+A legacy of 31 Years.
+India`s Oldest Investment & IPO website.
+Most Trusted by Investors across India.
Table of Contents
- GMP
- Reviews
- Subscription
- Allotment
What is the latest news relating to Sai Life Sciences IPO?
Sai Life Sciences has received Sebi green signal to enter the capital market on October 31, 2024.
Who is the promoter of Sai Life Sciences IPO?
The company’s promoters are KANUMURI RANGA RAJU, KRISHNAM RAJU KANUMURI, KANUMURI MYTREYI, SAI QUEST SYN PRIVATE LIMITED, MARIGOLD PARTNERS, SUNFLOWER PARTNERS, TULIP PARTNERS AND LILY PARTNERS
What are the Objects of Sai Life Sciences IPO?
The Company proposes to utilise the Net Proceeds towards funding the following objects:
1.Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company; and
2.General corporate purposes.
What is the business of Sai Life Sciences?
Sai Life Sciences is an innovator-focused, contract research, development, and manufacturing organization (“CRDMO”). It provides end to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (“NCE”), to global pharmaceutical innovator companies and biotechnology firms.
It possess both (a) discovery / contract research (“CRO”) and (b) chemistry, manufacturing, and control (“CMC”) / contract development and manufacturing organization (“CDMO”) capabilities. It is the fastest-growing Indian CRDMOs among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR from Financial Year 2022 to Financial Year 2024. Its CRDMO platform provides multiple entry points for it to acquire customers in the intermediate stages of their new drug discovery to commercialization journey.
It is also one of the few CRDMOs to have a unique delivery model of having research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), United States (“US”) and Manchester, United Kingdom (“UK”), complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. During the Financial Year 2024, it served more than 280 innovator pharmaceutical companies, including 18 of the top 25 pharmaceutical companies (in terms of revenue for the calendar year 2023), across regulated markets, including the US, the UK, Europe and Japan.
During the Financial Year 2024, it also provided CRO services to more than 60 customers on an ongoing basis, for their integrated drug discovery programs. As of March 31, 2024, its CDMO product portfolio included more than 150 innovator pharmaceutical products, including 38 products that were supplied for manufacturing of 28 commercial drugs.
For more information, click www.sailife.com
Sai Life Sciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate
|
Sai Life Sciences IPO Details |
|
| IPO opens on | November 2024 |
| IPO closes on | November 2024 |
| Issue Type | Book Built Issue IPO |
| Issue Size | ? Shares / Rs ? Crore |
| * Fresh Issue | ? Shares / Rs 800 Crore |
| * Offer for Sale | 61,573,120 shares/ Rs.? Crore |
| Face Value per share: | Rs. 1 |
| Price Band | Rs.? |
| Retail Discount | Rs 0 per share |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | 51 Shares |
| Listing will at | BSE, NSE |
|
Shares offered in |
Shares | Rs. in Cr |
| QIB (75 %) | ||
| NII (15 %) | ||
| RII (10 %) | ||
| Employees | – | – |
| Total Shares | ||
| Retail portion will be oversubscribed by | ? Forms. | |
| How to apply in Sai Life Sciences IPO? |
Amount Rs. |
|
| Min Retail Application | Shares | |
| Max Retail Application | Shares | |
| Small HNI (Min) application | Shares | |
| Small HNI (Max) application | Shares | |
| Big HNI Application | Shares | |
|
What is the timetable of Sai Life Sciences IPO? |
|
| IPO opens on | November 2024 |
| IPO Closes on | November 2024 |
| IPO Allotment on | November 2024 |
| Unblocking of ASBA | November 2024 |
| Credit of Shares | November 2024 |
| Listing on | November 2024 |
| Registered Office of Sai Life Sciences | |
| Plot No. DS- 7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal – Malkajgiri District, Hyderabad 500 078, Telangana, India | |
| Who are the Lead Managers of Sai Life Sciences IPO? Kotak Mahindra Capital Company Ltd IIFL Securities Ltd Jefferies India Pvt ltd Morgan Stanley India Company |
|
| Registrar to IPO | |
| KFin Technologies Limited |
|
Sai Life Sciences IPO Financial & Analytical Ratios |
||||
| Year | Total Income | Net Profit | EPS | RoNW |
| Rs. in Cr | Rs.in Cr | Rs. | % | |
| 2021-22 | 898 | 6.23 | 0.35 | 0.71 |
| 2022-23 | 1245 | 9.99 | 0.55 | 1.12 |
| 2023-24 | 1494 | 82.81 | 4.39 | 8.13 |
| Book Value of the Share on 31.03.2024 |
Rs. | 53.94 | ||
| BV after the FPO | Rs. | ? | ||
| Offer Price at Cap | Rs. | ? | ||
| Sai Life Sciences IPO Ratio Analysis |
|
| Price /EPS | ? |
| Price/Book Value Ratio | ? |
| Price/BV after IPO | ? |
How Sai Life Sciences IPO compares with the Peers?
| As on date of DRHP | FV | Total | PE |
| Rs. | Income | Ratio of | |
| Rs. In Cr | |||
| Sai Life Sciences | 1 | 1465 | ? |
| Divi’s Laboratories | 2 | 7845 | 79.51 |
| Suven Life Sciences | 1 | 1051 | 78.36 |
| Syngene | 10 | 3489 | 61.70 |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Sai Life Sciences IPO Review
We will update our Review & Guidance, once the price band and other details are announced by the company.
Quicklinks
